Transine Therapeutics, a biotechnology company developing a novel class of therapeutic RNAs based on its pioneering SINEUP platform technology, appointed Jan Thirkettle, Ph.D. as CEO.
Viracta Therapeutics Inc., a precision oncology company targeting virus-associated malignancies, appointed Ayman El-Guindy, Ph.D., as chief scientific officer.
Travecta Therapeutics appointed Charles S. Ryan, J.D., Ph.D., as president and CEO.
Richard Morris has become chief financial officer for Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies.
Amphista Therapeutics, a biopharmaceutical company developing oncology drugs through its targeted protein degradation technology, added Martin O’Rourke as head of drug discovery and James Osborne as director of chemistry.
Malene Jensen has become VP clinical development at Medivir AB. She assumes the role after the summer, at the latest October 1, 2021. She will also join the company’s executive team.
Oxular Limited, a leading retinal therapeutics development company, appointed Dr. Friedrich (Fritz) Asmus as chief medical officer.
Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, appointed Michael S. Hanna, M.D., FACC, as chief medical officer.
Hikma Pharmaceuticals PLC made Patrick Genestin VP, business development, Generics.
In March 2020 our own experience of engaging with the rest of the world profoundly changed. This is as true in medicine as everywhere else – the big question is now how much of what has been so rapidly adopted will be retained in future years. And what does this mean for pharma?
